Updates to the approach pathologists use to classify myelodysplastic neoplasm (MDS), formally known as myelodysplastic syndrome, are expected to improve treatment decision-making for patients, according to a new publication by the College of American Pathologists (CAP).
For the full article click here: New classifications transform diagnosis of rare blood and bone marrow disorder, CAP says